NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of MabThera/Rituxan (Rituximab) Plus Chemotherapy As First-Line Treatment in Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

NCT01340443

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Diffuse Large B-Cell Lymphoma

Countries: China

This observational study will evaluate the safety and efficacy of MabThera/Rituxan (rituximab) plus chemotherapy as first-line treatment in patients with diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL). Data will be collected from each patient during the 6 months of induction treatment and for up to 3 years of follow-up.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed CD20+ diffuse large B-cell lymphoma or follicular lymphoma
* Treatment with MabThera/Rituxan as per locally approved China package insert
* Documented patient with medical records

Exclusion Criteria:

* Previous treatment for diffuse large B-cell lymphoma or follicular lymphoma

Locations (24)

Beijing, China
Changchun, China
Changsha, China
Changzhou, China
Daqing, China
Foshan, China
Fuzhou, China
Fuzhou, China
Guangzhou, China
Guiyang, China
Hangzhou, China
Hefei, China
Hohhot, China
Jinan, China
Kunming, China
Lanzhou, China
Nanjing, China
Shijiazhuang, China
Taiyuan, China
Wuhan, China
Xi'an, China
Zhengzhou, China
Zhengzhou, China
Zhongshan, China